• dysfunction
  • If successful, the proposed STTR Phase I research will confirm the usefulness of this approach for significantly enhanced treatment of the hyperphosphatemia and bone dysfunction of Stage 5 CKD. (sbir.gov)
  • assessment
  • This report provides comprehensive information on the therapeutic development for Hyperphosphatemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. (sbwire.com)